{"disease":{"id":"solid-cancers","name":"solid cancers"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05228106","title":"68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","has_results":false},{"nct_id":"NCT01296555","title":"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":674,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07427186","title":"Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT06999538","title":"Real-life Performance Evaluation of the LiFlow X-ray Platform","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT04844489","title":"Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People","phase":"NA","overall_status":"COMPLETED","enrollment_count":377,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06799637","title":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT06939764","title":"Application of the sG8 Scale in Real-World Geriatric Oncology Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":346,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT07238075","title":"ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"Adcytherix SAS","has_results":false},{"nct_id":"NCT03289962","title":"A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT07371663","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"Beijing Tide Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT07510841","title":"JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":228,"lead_sponsor_name":"Biotech Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02323191","title":"A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02304809","title":"Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":216,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT07167381","title":"xDRIVE for Florida-based Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"First Ascent Biomedical Inc.","has_results":false},{"nct_id":"NCT06253520","title":"Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT02174172","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03512340","title":"Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Surface Oncology","has_results":false},{"nct_id":"NCT05639751","title":"PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT05838768","title":"Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":123,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06614751","title":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Danatlas Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07092748","title":"A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Zhejiang Hisun Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT03340506","title":"Dabrafenib and/or Trametinib Rollover Study","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02408861","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03956680","title":"An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04029922","title":"Study of MT-5111 in HER2-positive Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Molecular Templates, Inc.","has_results":false},{"nct_id":"NCT07071103","title":"Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Chuangzhen Chen","has_results":false},{"nct_id":"NCT07003022","title":"Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04802174","title":"Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03254732","title":"Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":33,"lead_sponsor_name":"Polaris Group","has_results":false},{"nct_id":"NCT03388632","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00909740","title":"A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT07058948","title":"Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06883539","title":"A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"LaunXP Biomedical Co., Ltd.","has_results":false},{"nct_id":"NCT06825455","title":"Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT01875601","title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07170293","title":"Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT03860207","title":"Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Y-mAbs Therapeutics","has_results":true},{"nct_id":"NCT00886782","title":"A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07475182","title":"Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Hainan Cancer Hospital","has_results":false},{"nct_id":"NCT06630247","title":"A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT07479667","title":"An Antibody-armored Dendritic Cell in Patients With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":8,"lead_sponsor_name":"Shanghai Cell Therapy Group Co.,Ltd","has_results":false},{"nct_id":"NCT07274449","title":"Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06682806","title":"A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT02714374","title":"GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Andrew Lowy","has_results":false},{"nct_id":"NCT06130254","title":"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03842865","title":"Expanded Access of Vigil in Solid Tumors","phase":"","overall_status":"TEMPORARILY_NOT_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Gradalis, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}